Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inari Medical reports robust Q4 earnings and eyes international expansion

Inari Medical's Q4 2022 earnings call highlighted strong revenue growth, operational challenges, and strategic opportunities for market expansion and product innovation.
The company's focus on patient outcomes, superior product performance, and international growth positions it for continued success in 2023 and beyond.
Efforts to optimize gross margins, manage operating expenses, and drive market adoption present key areas for Inari's future financial performance and profitability.
With a clear revenue guidance for 2023 and a commitment to sustained operating profitability, Inari Medical demonstrates a strategic roadmap for sustainable growth.

Inari Medical reports robust Q1 earnings, eyes sustained profitability

Inari Medical's Q1 earnings call highlighted strong financial performance, growth strategies, and product innovations. Challenges include competitive dynamics and assessing seasonality trends. The company is well-positioned for sustained growth and market expansion.

Inari Medical reports record revenue and eyes Asian market expansion

Inari Medical's Q2 2023 performance reflects robust financial growth, international expansion, and a strategic focus on addressing unmet needs in the CVD market.
With a strong product portfolio, sustained profitability, and market development initiatives, Inari Medical is well-equipped to capitalize on growth opportunities and drive innovation.
Challenges in market entry, product redesign timelines, and regulatory approvals are being navigated as the company aims for sustained growth and market leadership in the medical device sector.

Inari Medical reports robust Q3 earnings, acquires LimFlow for growth

Inari Medical's Q3 performance reflects strong financial growth, operational improvements, and strategic acquisitions driving future prospects.
While challenges like declining margins and delayed profit targets exist, opportunities in new markets, product pricing, and synergies offer avenues for sustained growth.
The LimFlow acquisition positions Inari well in the CLTI market, with a focus on revenue growth, operational efficiency, and market expansion.
Overall, Inari's confidence in its core business and strategic moves like the LimFlow acquisition signal a positive trajectory and growth outlook.

Inari Medical reports record revenue, eyes sustained profitability amid challenges

Inari Medical's Q4 2023 performance showcased strong revenue growth, operational progress, and a strategic focus on market leadership and patient care.
While facing challenges such as regulatory scrutiny and increased operating expenses, the company remains optimistic about revenue growth and sustained profitability.
Opportunities lie in diversified revenue streams, international expansion, and product portfolio enhancements, positioning Inari for continued growth and market leadership.
Overall, Inari Medical's strategic initiatives and financial performance indicate a resilient and growth-oriented trajectory in the medical device industry.

Inari Medical reports record Q1 revenue, raises full-year guidance

Inari Medical's Q1 performance reflects robust revenue growth, strategic investments, and international expansion, positioning the company for sustained profitability and market leadership.
While facing challenges in competition and market dynamics, Inari's strengths in innovation, global performance, and product development offer avenues for growth and differentiation.
The company's focus on operational efficiency, strategic investments, and product enhancements align with opportunities in expanding toolkits, new therapies, and market presence.

Inari Medical reports record revenue, eyes sustained profitability and global expansion

Inari Medical's Q2 2024 performance reflects strong revenue growth but with operating losses, signaling a need for cost management strategies.
The company's strategic strengths lie in sustained profitability projections, successful business integrations, and expansion into key international markets.
Challenges include leadership transition risks, operational hurdles in new markets, and the need to meet high market expectations with upcoming data releases.
Opportunities for Inari include optimizing costs, leveraging growth in China and Japan, capitalizing on new product adoption, and driving further market expansion.

Inari Medical reports record revenue and eyes global expansion

Inari Medical's Q3 performance reflects robust revenue growth and strategic focus on expanding therapies globally.
The company's strengths lie in revised revenue guidance, upcoming profitability, and promising study outcomes.
Challenges include managing expenses, reducing losses, and sustaining high margins amidst market competition.
Opportunities abound in driving growth, capitalizing on new therapies, and expanding market presence internationally.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Inari investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws,.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Inari Medical, Inc. (NARI) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

Inari Medical, Inc. (NARI) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky, LLP Investigates

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) investors concerning the Company's possible violations of federal securities laws. On February 28, 2024, Inari announced that it had received a civil investigative demand from the U.S. Department of Justice “in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act” requesting information.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Inari Medical, Inc. (NARI) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 28, 2024, Inari announced that it had received a civil investigative demand from the U.S. Department of Justice “in connection with an investigation under the fede.

The Law Offices of Frank R. Cruz Announces Investigation of Inari Medical, Inc. (NARI) on Behalf of Investors

Inari Medical, Inc. Being Investigated on Behalf of Inari Medical, Inc. Investors. Contact Levi & Korsinsky For Details

NEW YORK , March 2, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Inari Medical, Inc. (NASDAQ: NARI) resulting from allegations that Inari Medical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Inari Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Inari Medical, Inc. Investors to Inquire About Securities Class Action Investigation - NARI

NEW YORK--(BUSINESS WIRE)---- $NARI #ClassActionInvestigation--The law firm of Kirby McInerney LLP is investigating potential claims against Inari Medical Inc. (“Inari” or the “Company”) (NASDAQ:NARI). The investigation concerns whether Inari and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On February 28, 2024, Inari Medical released its financial results for the fourth quarter and the full year of 2023.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Inari Medical, Inc. (NARI)

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Inari Medical, Inc. (NASDAQ: NARI) resulting from allegations that Inari Medical may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Inari Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Inari Medical, Inc. Investors to Inquire About Securities Class Action Investigation – NARI

Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.

Inari Medical (NARI) Q4 Earnings Improve Y/Y, Gross Margin Down

Inari Medical, Inc. (NARI) Q4 2023 Earnings Call Transcript

IRVINE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2023.

Inari Medical Reports Fourth Quarter 2023 Financial Results

IRVINE, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce Fourth Quarter and Full Year 2023 Financial Results

argenx

Axsome Therapeutics

Azenta

Vericel

While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their earnings calls, the reality is that the fundamentals now favor other (safer) areas of the economy.

5 medical stocks growing earnings by triple digits

Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.

Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand

IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance.

Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance

ALISO VIEJO, Calif. , Jan. 8, 2024 /PRNewswire/ -- Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced the appointment of Rhonda Robb as President and Chief Executive Officer.

OKAMI MEDICAL APPOINTS RHONDA ROBB AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

IRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45AM Pacific Time.

Inari Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock?

Inari Medical, Inc. (NARI) Up 17.1% Since Last Earnings Report: Can It Continue?

Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.

Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome

Clinical study randomizing up to 1,200 patients designed to help change guidelines in treating intermediate-risk Pulmonary Embolism (PE) patients globally Clinical study randomizing up to 1,200 patients designed to help change guidelines in treating intermediate-risk Pulmonary Embolism (PE) patients globally

Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)

IRVINE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the close of its acquisition of LimFlow S.A., a privately-held pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI).

Inari Medical Closes Acquisition of LimFlow

Inari Medical's Q3 2023 revenue was up over 31% YoY, with $3.2M in net income and $351.3M in cash and investments. The acquisition of LimFlow presents a potential $1.5B annual opportunity in the US for Inari Medical. Despite competition and potential macroeconomic risks, Inari Medical is expected to be a top-performing stock in the next three to five years.

Inari Medical: Top Buy For End Of 2023 And 2024

Inari Medical, Inc. (NARI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Inari Medical, Inc. (NARI) Loses -27.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.

Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates

Inari Medical, Inc. (NASDAQ:NARI ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants John Hsu - VP, IR Drew Hykes - President and CEO Mitch Hill - CFO Tom Tu - CMO Conference Call Participants Kallum Titchmarsh - Morgan Stanley Larry Biegelsen - Wells Fargo Bill Plovanic - Canaccord Marie Thibault - BTIG Adam Maeder - Piper Sandler Mike Sarcone - Jefferies Richard Newitter - Truist Securities David Rescott - Baird Chris Pasquale - Nephron Research Operator Good day and welcome to Inari Medical Incorporated Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

News for Inari Medical Stock (NARI)